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revention and Treatment
Tale of Two Strategies*
eorge A. Diamond, MD, FACC,
anjay Kaul, MD, FACC
os Angeles, California
It was the best of times, it was the worst of times,
it was the age of wisdom, it was the age of foolishness,
it was the epoch of belief, it was the epoch of incredulity,
it was the season of Light, it was the season of Darkness . . .
Charles Dickens (1)
Dickensian duo of contrasting imperatives underlies the
urrent management of atherosclerotic heart disease: to treat
he anatomic stenosis causing myocardial ischemia and to
revent the plaque disruption causing myocardial infarction.
he former leads us to do stress tests and angiograms to
dentify flow-limiting lesions and then to crush them by
irect surgical intervention, while the latter leads us to
dentify risk factors, such as cholesterol, and prescribe drugs,
uch as statins, to mitigate those risks.
A host of clinical trials support each approach. In general,
reatment is better suited to unstable coronary syndromes,
nd prevention is better suited to stable coronary disease.
he recent COURAGE (Clinical Outcomes Utilizing Re-
ascularization and Aggressive Drug Evaluation) trial, for
xample, showed that percutaneous coronary intervention
PCI) did not improve outcomes when added to optimal
edical therapy in patients with stable disease (2). It is
ncertain, however, if these findings are applicable to older
ubjects, given their under-representation in the pivotal
rials upon which current guidelines are based.
See page 37
In this issue of the Journal, Afilalo et al. (3) shed new
ight on the effectiveness of statins in “elderly” patients with
nown coronary disease. In their meta-analysis of 9 trials
nrolling patients between 65 and 82 years of age, statins
educed all-cause mortality by 22% over 5 years of follow-
p. Rates of nonfatal infarction, stroke, and revasculariza-
ion were reduced even more. Importantly, the magnitude of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.$
From the Division of Cardiology, Cedars-Sinai Medical Center and David Geffen
chool of Medicine, University of California, Los Angeles, California.enefit was substantially larger than previously reported and
ncreased with age, a 50% mortality reduction being ob-
erved in those over 80 years of age. Although the authors
ere unable to perform a formal assessment of safety, a
ecent review concluded that statins are “remarkably safe,”
ven in the elderly (4).
A limitation of this meta-analysis is the unavailability of
atient-level data, which would have permitted an assess-
ent according to pertinent clinical and demographic sub-
roups. Such details can be important, because patients in
linical trials differ from those in routine clinical practice. In
ddition, the time to onset of benefit and the effect of
ow-density lipoprotein (LDL) cholesterol (at baseline and
n treatment) were not evaluated.
Nonetheless, using a previously published empirical sur-
ival model (5), the study has substantial practical relevance
Table 1). As suggested by Afilalo et al. (3), an 85-year-old
an with known disease has a greater baseline risk (18.8%
s. 1.3%), and therefore obtains a greater benefit (8.9% vs.
.4%) from statin treatment compared with an otherwise
imilar 55-year-old man. Thus, although the absolute gain
n survival is lower in the 85-year-old (2.1 vs. 4.3 years), it
s proportionately greater (75% vs. 23%) relative to baseline
xpectations of survival (2.8 vs. 18.8 years). All things being
qual, then, the older we become, the more value we should
scribe to each additional year of life (and to the treatment
hat provides it).
Two practical problems, however, continue to plague the
ffectiveness of statin therapy in clinical practice. First,
ong-term adherence to therapy remains poor, averaging
nly 62% over 2 years (6–10). Second, the so-called “treat-
ent gap” (the proportion of statin candidates not receiving
tatin treatment) remains large, especially among the el-
erly. In one study, only 57% of “high-risk” patients
ttained LDL 100 mg/dl, and 18% attained LDL 70
g/dl (11). Preferred drug lists and tiered formularies
urther compound this misutilization (12).
Meanwhile, the use of PCI continues to increase despite
he lack of equivalent evidence of outcomes benefit. Current
eimbursement policy actually encourages such misuse.
nce drugs and devices are approved for marketing, physi-
ians often use them in unapproved ways, and payers
eimburse such “off-label” use to the same degree as “on-
abel” use.
Fine-tuning these financial incentives might help to close
he treatment gap and increase adherence to statin therapy
13). Suppose the Center for Medicare and Medicaid
ervices (CMS) discounted a drug’s price, not by some fixed
mount as it does now, but in direct proportion to its proven
herapeutic benefit, so that one with more benefit is awarded
higher discount than another with less benefit. For
xample, imagine that one statin costing $2 per day (call it
ositor) has a discount of 90% because it is proven to
mprove survival, whereas a competitive statin also costing
2 per day (call it Negator) has a discount of 10% because it
o
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January 1/8, 2008:46–8 Editorial Commentnly improves some surrogate marker. As a result, patients
ay $6/month for Positor versus $54/month for Negator.
hich of the two would you and your patient prefer?
Because the total price of the prescription does not
hange (with CMS picking up the difference), a high
iscount will not erode the manufacturer’s profits. In fact,
rofits are more likely to soar as a result of facilitated access
o the less-costly drug and favorable shifts in market share.
he CMS might even exploit this windfall to negotiate
olume discounts with the manufacturer, thereby offsetting
ome of the cost of the plan. Although such negotiations are
urrently prohibited by existing law, the issue is under
ongressional review. Thus, as a result of these incentives,
he manufacturer is rewarded with competitive advantages
or documenting the benefits of its drugs, and the patient is
ewarded with better access to these benefits at more
ffordable prices.
Critics might argue that this plan requires a huge new
ureaucracy. On the contrary, the needed infrastructure is
argely in place. The Food and Drug Administration already
alls on advisory panels to help decide if a drug meets
tandards of efficacy and safety. All it need do is empower
hese panels with the additional authority to set the discount
or the drug based on the scientific evidence they are already
eviewing. As new data become available, manufacturers
ould request a new review, just as they now petition for
abeling changes.
Innovative strategies such as this are already being piloted
n the private sector. Over the past decade, health plans have
ought to save money by charging higher patient copay-
ents for brand-name drugs to encourage the use of
ower-cost generics. Now they are lowering copayments for
rugs with proven preventive benefit (14). If patients no
onger have to pay the cost of a statin, so goes the reasoning,
hey will more likely adhere to treatment, thereby forestall-
ng higher-cost eventualities (stroke, reinfarction, revascu-
arization). Aetna will conduct a formal evaluation of this
ew strategy later this year, by waiving copayments for
tatins (along with a few other agents) in post-infarction
atients and tracking subsequent outcome and cost. From
he patients’ perspective, this might be the closest thing
here is to getting something for nothing.
The CMS could attach similar financial incentives to the
erformance of PCI by reimbursing approved “on-label” use
t a higher level than for unapproved “off-label” use. Simply
Expected Benefit of Statins for Secondary Preve
Table 1 Expected Benefit of Statins for Sec
Age
(yrs)
Expected
Survival
(yrs)
Absolute
Annual
Mortality (%)
85 2.8 18.8
70 8.3 5.0
55 18.8 1.3
All values are estimated using a previously published empirical survivut, if payment drives utilization, and utilization drivesutcome, payment can drive outcome. Unlike “pay-for-
erformance,” for which there is little proof of effectiveness
15), evidence-based reimbursement would: 1) target the
xpectation of benefit rather than actual outcome; 2) rely on
mpirical data rather than consensus opinion; 3) apply to
ndividuals rather than groups; and 4) be large in size and
mmediate in impact.
If we are to pay for preventive care in proportion to its
linical value, consumers will need to be informed about
hese values. Currently, manufacturers are faced with sub-
tantial regulatory hurdles in attempting to provide truthful
nformation to physicians and patients about the use of their
roducts. Insurers, patient advocacy groups, and the Sur-
eon General’s office are not so constrained, and are free to
nform the public truthfully about the value even of “off-
abel” uses. They should be encouraged to do so.
Although these are revolutionary proposals, so too was
he original Medicare law. Its passage instantly assured the
lderly of unfettered access to health care, but it also
ngendered a deep disconnect between what the providers
f that care should do (according to the evidence), and what
hey are paid to do (according to reimbursement policies).
he statin treatment gap is but one example.
This situation will not change unless and until we realign
he financial and scientific incentives and begin rewarding
aregivers, not for the prodigal provision of products and
ervices, but for the enlightened provision of therapeutic
enefit. Evidence-based reimbursement can be the bridge to
his “far, far better thing” (1).
eprint requests and correspondence: Dr. George A. Diamond,
408 Wild Oak Drive, Los Angeles, California 90068. E-mail:
adiamond@pol.net.
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